An observational study in Pulmonary Diseases, Respiratory Disease and Esophageal Diseases, sponsored by Chinese Academy of Sciences. Recruiting at 1 site in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-13.
Sponsored by Chinese Academy of Sciences · Observational
This multicenter, prospective study aims to evaluate the real-world clinical utility of chest X-ray (CXR) for large-scale thoracic disease screening. Adult participants presenting for health examinations will undergo digital CXR screening, and any suspected abnormalities will be confirmed via a gold standard reference, such as a chest CT scan or clinical follow-up. The primary outcome measure is the detection rate (screening yield) of confirmed thoracic conditions. Secondary measures will assess diagnostic accuracy (sensitivity and specificity), false-positive rates, and multi-center reading consistency. By providing prospective, large-cohort evidence, this research seeks to validate the cost-effectiveness and feasibility of CXR in identifying early-stage lung, pleural, and cardiac abnormalities, ultimately guiding public health strategies and optimizing early medical intervention.
1,158 studies on the registry are indexed under Lung Diseases; 182 are open to participants now.
This study's planned enrollment of 300,000 is above the median of 200 across 315 observational studies indexed under Lung Diseases.
Browse Lung Diseases studies →Chinese Academy of Sciences is the lead sponsor of 65 studies on the registry; 13 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Participants who received radiography for thoracic disease screen.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Overall Detection Rate of Thoracic Diseases
Defined as the proportion of subjects with positive X-ray findings that are subsequently confirmed by a gold standard reference (e.g., CT scan, pathology, or comprehensive clinical follow-up) out of the total screened population.
Time frame: Through study completion, an average of 1 year.
Screening Yield
Defined as the number of newly identified, clinically significant thoracic disease cases detected per 1,000 screening examinations.
Time frame: Through study completion, an average of 1 year.
Diagnostic Performance Metrics
Evaluating the diagnostic accuracy of chest X-rays using CT as the gold standard. Metrics include: Sensitivity and Specificity, Positive Predictive Value (PPV) and Negative Predictive Value (NPV), Miss Rate (False Negative Rate), with a specific focus on early-stage lung nodules and occult pneumonia.
Time frame: Through study completion, an average of 1 year.
Multi-center Consistency and Inter-reader Reliability
Assessed using agreement coefficients (e.g., Cohen's Kappa or Intraclass Correlation Coefficient \[ICC\]) among radiologists with varying levels of experience across different participating centers when interpreting the radiographs.
Time frame: Through study completion, an average of 1 year.
Disease-Specific Detection Rates
Stratified detection rates for specific thoracic abnormalities, including but not limited to pulmonary nodules (lung nodules), pneumonia, pneumothorax, cardiomegaly, and pleural effusion.
Time frame: Through study completion, an average of 1 year.
Start is estimated for May 2026; primary completion for Dec 2028, 31 months later.
Of 131 non-industry observational studies under Lung Diseases, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 95. This study's planned 31 months is below that.
Counting every sponsor, half of 153 studies reached it within 36 months; a quarter within 15 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chinese Academy of Sciences